Patterson Companies, Inc. (NASDAQ:PDCO) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in shares of Patterson Companies, Inc. (NASDAQ:PDCO - Free Report) by 61.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 201,274 shares of the company's stock after selling 320,316 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.23% of Patterson Companies worth $4,396,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PDCO. Miller Howard Investments Inc. NY raised its holdings in Patterson Companies by 2.3% in the 2nd quarter. Miller Howard Investments Inc. NY now owns 19,545 shares of the company's stock valued at $471,000 after acquiring an additional 442 shares during the last quarter. KBC Group NV boosted its stake in Patterson Companies by 32.7% during the third quarter. KBC Group NV now owns 2,757 shares of the company's stock worth $60,000 after buying an additional 680 shares during the last quarter. Hsbc Holdings PLC grew its holdings in Patterson Companies by 6.2% in the 2nd quarter. Hsbc Holdings PLC now owns 14,184 shares of the company's stock valued at $341,000 after buying an additional 828 shares in the last quarter. LRI Investments LLC increased its stake in shares of Patterson Companies by 201.2% in the 2nd quarter. LRI Investments LLC now owns 1,262 shares of the company's stock worth $30,000 after acquiring an additional 843 shares during the last quarter. Finally, Bfsg LLC raised its holdings in shares of Patterson Companies by 8.2% during the 3rd quarter. Bfsg LLC now owns 12,250 shares of the company's stock worth $268,000 after acquiring an additional 925 shares during the period. Hedge funds and other institutional investors own 85.43% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PDCO shares. JPMorgan Chase & Co. cut their price objective on shares of Patterson Companies from $29.00 to $26.00 and set a "neutral" rating for the company in a research report on Thursday, August 29th. Stifel Nicolaus reduced their price target on shares of Patterson Companies from $25.00 to $24.00 and set a "hold" rating on the stock in a research report on Thursday, December 5th. Mizuho started coverage on Patterson Companies in a research note on Wednesday, December 4th. They set a "neutral" rating and a $23.00 target price for the company. Bank of America decreased their price target on Patterson Companies from $31.00 to $29.00 and set a "buy" rating on the stock in a research note on Thursday, August 29th. Finally, Robert W. Baird raised their price objective on Patterson Companies from $25.00 to $31.00 and gave the stock a "neutral" rating in a research report on Thursday. Eleven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $26.24.

Insider Activity at Patterson Companies

In other news, CEO Donald Zurbay sold 1,962 shares of the company's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $23.08, for a total value of $45,282.96. Following the completion of the transaction, the chief executive officer now owns 222,736 shares in the company, valued at approximately $5,140,746.88. This represents a 0.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.90% of the stock is currently owned by corporate insiders.

Patterson Companies Stock Up 0.3 %

Shares of NASDAQ PDCO traded up $0.10 during mid-day trading on Friday, hitting $31.08. The company had a trading volume of 1,496,980 shares, compared to its average volume of 1,008,700. The company has a market capitalization of $2.74 billion, a PE ratio of 18.16, a price-to-earnings-growth ratio of 2.72 and a beta of 1.00. The business's 50-day simple moving average is $21.52 and its 200 day simple moving average is $22.88. Patterson Companies, Inc. has a 1-year low of $19.45 and a 1-year high of $31.79. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.37 and a quick ratio of 0.76.

Patterson Companies (NASDAQ:PDCO - Get Free Report) last announced its quarterly earnings data on Thursday, December 5th. The company reported $0.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.02). Patterson Companies had a net margin of 2.37% and a return on equity of 19.77%. The company had revenue of $1.67 billion during the quarter, compared to analysts' expectations of $1.65 billion. During the same quarter in the previous year, the business posted $0.50 EPS. The business's quarterly revenue was up 1.0% compared to the same quarter last year. On average, analysts predict that Patterson Companies, Inc. will post 2.27 earnings per share for the current year.

Patterson Companies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Wednesday, October 16th were given a dividend of $0.26 per share. The ex-dividend date was Friday, October 18th. This represents a $1.04 annualized dividend and a dividend yield of 3.35%. Patterson Companies's dividend payout ratio (DPR) is currently 60.82%.

About Patterson Companies

Patterson Companies, Inc engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada. The company operates through three segments: Dental, Animal Health, and Corporate segments. The Dental segment offers consumable products, including infection control, restorative materials, and instruments; basic and advanced technology and dental equipment; practice optimization solutions, such as practice management software, e-commerce, revenue cycle management, patient engagement solutions, and clinical and patient education systems.